News

Cadence Adds New Class 7 (10,000) Cleanroom in Connecticut

Cadence, Inc., a leading contract manufacturer of medical devices, announced today the completion of a certified International Organization for Standardization (ISO) Class 7 (10,000) cleanroom at its Connecticut manufacturing facility.  The new cleanroom is dedicated to the production of innovative medical device components and subassemblies.

“The cleanroom opens the door to new, exciting opportunities for our manufacturing facility,” stated Chris Haddad, the Director of Operations at Cadence’s Connecticut facility.  “Adding the new cleanroom and citric passivation allows us to expand our service offerings for existing and new customers, as well as streamlines our supply chain, reduces costs, and complements our laser processing expertise.”

The new cleanroom further enhances Cadence’s portfolio as a leading, vertically integrated contract manufacturing partner of medical devices worldwide.  Cadence now offers certified cleanroom manufacturing at three of its facilities for maximum customer flexibility.

Located in Suffield, the Connecticut facility is dedicated to advanced laser processing technologies.  Virtually tour Cadence’s Connecticut facility here.

Read more here.

Recent News

02/22/2024

Protected: Don’t Miss These Spring Talent Events

There is no excerpt because this is a protected post.

02/21/2024

SRI selected as spoke for both ARPA-H Customer Experience Hub and Investor Catalyst Hub

SRI has been selected by the Advanced Research Projects Agency for Health (ARPA-H) to serve as a spoke within the Customer Experience Hub (CX Hub) and the Investor Catalyst Hub (IC Hub), as part of ARPANET-H, a nationwide health innovation network launched in September 2023. “Hundreds of organizations have been selected to join each network.

02/21/2024

ReAlta Life Sciences Announces Dosing of First Patient in Phase 2 Trial of RLS-0071 for Acute Exacerbations of Chronic Obstructive Pulmonary Disease

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a mid-stage clinical biotech company dedicated to saving lives by rebalancing the inflammatory response to address life-threatening diseases, announced enrollment of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of RLS-0071, an investigational new drug based on ReAlta’s novel EPICC peptide